Drug Interactions between clotrimazole and Ubrelvy

Consumer information for this interaction is not currently available.

ADJUST DOSE: Coadministration with inhibitors of CYP450 3A4, breast cancer resistance protein (BCRP), and/or P-glycoprotein (P-gp) may increase the plasma concentrations of ubrogepant based on in vivo and in vitro data. The proposed mechanism involves enhanced oral bioavailability as well as reduced clearance of ubrogepant due to inhibition of CYP450 3A4-mediated metabolism and BCRP/P-gp-mediated efflux in the intestine and liver. When ubrogepant was administered with the potent CYP450 3A4 inhibitor ketoconazole during in vivo studies, ubrogepant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 5.3- and 9.7-fold, respectively. When administered with the moderate CYP450 3A4 inhibitor verapamil, ubrogepant Cmax and AUC increased by 2.8- and 3.5-fold, respectively. Dedicated drug interaction studies have not been conducted to assess concomitant use of ubrogepant with weak CYP450 3A4 inhibitors and inhibitors of BCRP or P-gp transporters. Ubrogepant exposure is not expected to increase by more than 2-fold when used with weak CYP450 3A4 inhibitors per a conservative prediction from the manufacturer.

MANAGEMENT: The recommended dose of ubrogepant is 50 mg during concomitant treatment with weak CYP450 3A4 inhibitors and/or inhibitors of BCRP or P-gp. If needed, a second 50 mg ubrogepant dose may be administered at least 2 hours after the initial dose.